-
This second of a two-part article looking at the challenges faced by home health managers describes demonstration projects included in HR 1 that affect the home health industry.
-
In teaching health care providers how to care for patients at the end of life, many institutions forget to teach the providers that they need to care for themselves as well.
-
Attorneys general should play a role in advising state agencies and educating others about how laws and policies related to end-of-life care should be enforced, especially if they seem to be at odds with patient rights. The most salient example of this conflict has been the ongoing battle between end-of-life care advocates and law enforcement agencies.
-
New tool evaluates care options for seniors; JCAHO modifies patient safety goals
-
A total of 6.2% of hospital employees were nasal carriers of MRSA, with the rate highest among workers in long-term care (36%). In 4 of 10 families surveyed, family members were colonized by the same MRSA as the employee.
-
An antibiotic preparation meant for addition to animal feed was found to be contaminated with antibiotic resistance genes. Fortunately, the genes being used generally encode for resistance mechanisms that are already highly prevalent in gastrointestinal bacteria.
-
A substantial difference in clinical quality was found between the winners of the Health Grades Inc./J.D. Power & Associates Distinguished Hospital Award for Clinical Excellence winners and all other hospitals, Health Grades Inc. reports.
-
-
The arimidex, tamoxifen alone or in combination (ATAC) trial is a large-scale, international, industry-sponsored interventional, randomized study involving almost 10,000 early-stage postmenopausal breast cancer patients who were randomized to receive either anastrozole alone or in combination with tamoxifen, or tamoxifen alone.
-
Controversy exists regarding the best approach to early epidermoid cancers of the lip. Various approaches have been advocated, including surgery with or without postoperative radiotherapy, and low- dose rate (LDR) brachytherapy.
